文献速递乳腺MRUS乳腺X线

微钙化与瘤周水肿预测接受新辅助化疗的Luminal型乳腺癌患者的生存结局

Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy.
PubMed 文献 · Radiology · 2022-05-10

该回顾性研究纳入两家医院接受新辅助化疗后手术的Luminal型乳腺癌患者,开发队列318例、验证队列165例,分析MRI、超声和乳腺X线表现及临床病理变量与无远处转移生存(DMFS)和总生存(OS)的关系,并建立预测模型。新辅助化疗后MRI瘤周水肿、年龄小于40岁、临床N2或N3、淋巴血管侵犯与较差的DMFS相关;新辅助化疗前乳腺X线微钙化、新辅助化疗后MRI瘤周水肿、年龄大于60岁、临床T3或T4与较差的OS相关。验证队列中模型区分度良好(C指数DMFS 0.67-0.75,OS 0.70-0.77),可将预后分为低危和高危组(10年DMFS率79% vs 21%;10年OS率95%-96% vs 63%-67%)。

要点

  • 新辅助化疗后MRI瘤周水肿与Luminal型乳腺癌较差的DMFS和OS均相关。
  • 新辅助化疗前乳腺X线微钙化与较差的OS相关。
  • 模型在验证队列中区分度良好,C指数DMFS 0.67-0.75、OS 0.70-0.77。

核心结论

  • MRI表现(新辅助化疗后瘤周水肿、新辅助化疗前微钙化)及临床病理变量与接受新辅助化疗的Luminal型乳腺癌患者生存相关,预测模型区分度良好并可分层预后。

研究设计与样本

  • 回顾性研究,开发队列318例(远处转移68例、死亡54例),验证队列165例(远处转移37例、死亡14例),两队列中位年龄均为46岁;开发队列来自一家医院2003年1月至2015年7月,验证队列来自另一家医院2007年1月至2015年7月;回顾新辅助化疗前后MRI、超声、乳腺X线及临床病理资料;采用Cox回归在开发队列建立预测模型,并在验证队列检验。

关键影像表现/征象

  • 瘤周水肿定义为T2加权MRI上肿瘤周围的水样高信号。
  • 新辅助化疗后MRI瘤周水肿、年龄小于40岁、临床N2或N3、淋巴血管侵犯与较差的DMFS相关(均P < .05)。
  • 新辅助化疗前乳腺X线微钙化、新辅助化疗后MRI瘤周水肿、年龄大于60岁、临床T3或T4与较差的OS相关(均P < .05)。

诊断标准与关键数值

  • 验证队列中模型区分度C指数:DMFS 0.67-0.75,OS 0.70-0.77。
  • 验证队列中模型将预后分为低危和高危组:10年DMFS率79% vs 21%;10年OS率95%-96% vs 63%-67%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Little is known regarding findings at imaging associated with survival in patients with luminal breast cancer treated with neoadjuvant chemotherapy (NAC). Purpose To determine the relationship between imaging (MRI, US, and mammography) and clinical-pathologic variables in predicting distant metastasis-free survival (DMFS) and overall survival (OS) in patients with luminal breast cancer treated with NAC. Materials and Methods In this retrospective study, consecutive women with luminal breast cancer who underwent NAC followed by surgery were identified from the breast cancer registries of two hospitals. Women from one hospital between January 2003 and July 2015 were classified into the development cohort, and women from the other hospital between January 2007 and July 2015 were classified into the validation cohort. MRI scans, US scans, and mammograms before and after NAC (hereafter, referred to as pre- and post-NAC, respectively) and clinical-pathologic data were reviewed. Peritumoral edema was defined as the water-like high signal intensity surrounding the tumor on T2-weighted MRI scans. The prediction model was developed in the development cohort by using Cox regression and then tested in the validation cohort. Results The development cohort consisted of 318 women (68 distant metastases, 54 deaths) and the validation cohort consisted of 165 women (37 distant metastases, 14 deaths) (median age, 46 years in both cohorts). Post-NAC MRI peritumoral edema, age younger than 40 years, clinical N2 or N3, and lymphovascular invasion were associated with worse DMFS (all, P < .05). Pre-NAC mammographic microcalcifications, post-NAC MRI peritumoral edema, age older than 60 years, and clinical T3 or T4 were associated with worse OS (all, P < .05). The prediction model showed good discrimination ability (C index, 0.67-0.75 for DMFS and 0.70-0.77 for OS) and stratified prognosis into low-risk and high-risk groups (10-year DMFS rates, 79% vs 21%, respectively; and 10-year OS rates, 95%-96% vs 63%-67%, respectively) in the validation cohort. Conclusion MRI features and clinical-pathologic variables were identified that were associated with prolonged survival of patients with luminal breast cancer treated with neoadjuvant chemotherapy. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Kataoka in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kwon, Shin, Kim, et al. Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy. Radiology. 2022. PMID: 35536129. doi:10.1148/radiol.211509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。